Literature DB >> 11996942

Apolipoprotein B metabolism in humans: studies with stable isotope-labeled amino acid precursors.

Julian B Marsh1, Francine K Welty, Alice H Lichtenstein, Stefania Lamon-Fava, Ernst J Schaefer.   

Abstract

This article reviews the literature from 1986 to early 2001 relating to apoB100 and apoB48 kinetics in humans using amino acid precursors labeled with stable isotopes. The following subjects are reviewed: (1) methodology; (2) normal individuals and the effects of aging; (3) diet; (4) hereditary dyslipidemias: familial hypercholesterolemia, familial combined hyperlipidemia, cholesteryl ester storage disease, cholesteryl ester transfer protein deficiency, lipoprotein lipase deficiency, familial hypobetalipoproteinemia, and truncated forms of apoB; (5) hormonal perturbations: estrogen, insulin, diabetes, obesity, and growth hormone; (6) the nephrotic syndrome; and (7) the effects of the statin class of drugs. Because of the advances which have been made in mass spectrometry techniques, the advantages of using non-radioactive tracers in humans have made stable isotope kinetic studies the present day standard in this area of research.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11996942     DOI: 10.1016/s0021-9150(01)00709-2

Source DB:  PubMed          Journal:  Atherosclerosis        ISSN: 0021-9150            Impact factor:   5.162


  9 in total

Review 1.  Clinical pharmacological properties of mipomersen (Kynamro), a second generation antisense inhibitor of apolipoprotein B.

Authors:  Stanley T Crooke; Richard S Geary
Journal:  Br J Clin Pharmacol       Date:  2013-08       Impact factor: 4.335

2.  Metabolism of apoB lipoproteins of intestinal and hepatic origin during constant feeding of small amounts of fat.

Authors:  Chunyu Zheng; Katsunori Ikewaki; Brian W Walsh; Frank M Sacks
Journal:  J Lipid Res       Date:  2006-05-09       Impact factor: 5.922

3.  In silico modeling of the dynamics of low density lipoprotein composition via a single plasma sample.

Authors:  Martin Jansen; Peter Pfaffelhuber; Michael M Hoffmann; Gerhard Puetz; Karl Winkler
Journal:  J Lipid Res       Date:  2016-03-25       Impact factor: 5.922

Review 4.  Diabetic dyslipidaemia: from basic research to clinical practice.

Authors:  M-R Taskinen
Journal:  Diabetologia       Date:  2003-05-28       Impact factor: 10.122

5.  Both intestinal and hepatic lipoprotein production are stimulated by an acute elevation of plasma free fatty acids in humans.

Authors:  Hélène Duez; Benoît Lamarche; René Valéro; Mirjana Pavlic; Spencer Proctor; Changting Xiao; Linda Szeto; Bruce W Patterson; Gary F Lewis
Journal:  Circulation       Date:  2008-04-28       Impact factor: 29.690

Review 6.  Fatty liver, insulin resistance, and dyslipidemia.

Authors:  Martin Adiels; Marja-Riitta Taskinen; Jan Borén
Journal:  Curr Diab Rep       Date:  2008-02       Impact factor: 4.810

7.  Gender-specific differences in the kinetics of nonfasting TRL, IDL, and LDL apolipoprotein B-100 in men and premenopausal women.

Authors:  Nirupa R Matthan; Susan M Jalbert; P Hugh R Barrett; Gregory G Dolnikowski; Ernst J Schaefer; Alice H Lichtenstein
Journal:  Arterioscler Thromb Vasc Biol       Date:  2008-07-24       Impact factor: 8.311

8.  Characterizations of Hamster Retina as a Model for Studies of Retinal Cholesterol Homeostasis.

Authors:  Nicole El-Darzi; Natalia Mast; Brian Dailey; John Denker; Yong Li; Joseph Vance; Irina A Pikuleva
Journal:  Biology (Basel)       Date:  2021-10-06

9.  CDKN2B expression in adipose tissue of familial combined hyperlipidemia patients.

Authors:  Stuart D Horswell; Lee G D Fryer; Claire E Hutchison; Dlear Zindrou; Helen E Speedy; Margaret-M Town; Emma J Duncan; Rasheeta Sivapackianathan; Hetal N Patel; Emma L Jones; Adam Braithwaite; Max P A Salm; Claire K Y Neuwirth; Elizabeth Potter; Jonathan R Anderson; Kenneth M Taylor; Mary Seed; D John Betteridge; Martin A Crook; Anthony S Wierzbicki; James Scott; Rossi P Naoumova; Carol C Shoulders
Journal:  J Lipid Res       Date:  2013-10-08       Impact factor: 5.922

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.